Table 2. Comparison of clinicopathologic parameters between concordant and discordant cases.
| Characteristics | Concordant cases (n = 65) | Discordant cases (n = 14) | p-value | |
|---|---|---|---|---|
| Age (yr) | 57.5 ± 11.3 | 59.4 ± 9.0 | 0.184 | |
| BMI (kg/m2) | 24.1 ± 4.1 | 22.4 ± 3.5 | 0.820 | |
| Family history of breast cancer | 1 (1.5) | 1 (7.1) | 0.325 | |
| Radioisotope injection in surgery day | 0.380 | |||
| Yes | 37 (56.9) | 10 (71.4) | ||
| No | 28 (43.1) | 4 (28.6) | ||
| Location | 0.818 | |||
| Right | 31 (47.7) | 7 (50.0) | ||
| Left | 34 (52.3) | 7 (50.0) | ||
| Breast surgery | 0.417 | |||
| Breast-conserving surgery | 53 (81.5) | 12 (85.7) | ||
| Mastectomy | 12 (18.5) | 2 (14.3) | ||
| Axillary surgery | 0.174 | |||
| Sentinel lymph node biopsy | 61 (93.8) | 14 (100.0) | ||
| Axillary lymph node dissection | 4 (6.2) | - | ||
| Multifocality | 18 (27.7) | 3 (21.4) | 0.749 | |
| Clinical tumor size | 1.7 ± 0.9 | 1.8 ± 1.4 | ||
| Pathologic tumor size | 2.0 ± 0.9 | 1.6 ± 0.7 | ||
| Clinical T stage | 0.143 | |||
| 0 | 2 (3.1) | 1 (7.1) | ||
| 1 | 44 (67.7) | 12 (85.7) | ||
| 2 | 20 (30.8) | 1 (7.1) | ||
| Clinical N stage | 0.347 | |||
| 0 | 64 (98.5) | 14 (100.0) | ||
| 1 | 1 (1.5) | - | ||
| Pathologic T stage | 0.484 | |||
| 0 | 2 (3.1) | - | ||
| 1 | 38 (58.5) | 11 (78.6) | ||
| 2 | 25 (38.5) | 3 (21.4) | ||
| Axillary LN metastasis | 15 (23.1) | 1 (7.1) | 0.285 | |
| Histologic grade* | 0.288 | |||
| 1 | 9 (13.8) | 7 (50.0) | ||
| 2 | 36 (55.4) | 2 (14.3) | ||
| 3 | 18 (27.7) | 5 (35.7) | ||
| Existence of extensive intraductal component | 16 (24.6) | 3 (21.4) | 0.562 | |
| Estrogen receptor, positive | 52 (80.0) | 10 (71.4) | 0.486 | |
| Progesterone receptor, positive | 40 (61.5) | 8 (57.1) | 0.760 | |
| Her2/neu gene, positive | 5 (7.7) | 11 (78.6) | 0.383 | |
| Ki67 index | 0.523 | |||
| Low (< 14%) | 17 (26.2) | 6 (42.9) | ||
| High (≥ 15%) | 48 (73.8) | 8 (57.1) | ||
| Triple negative breast cancer | 6 (9.2) | 2 (14.3) | 0.298 | |
| Adjuvant chemotherapy | 38 (58.5) | 6 (42.9) | 0.286 | |
| Adjuvant radiotherapy | 42 (64.6) | 9 (64.3) | 1.000 | |
| Adjuvant hormone therapy | 40 (61.5) | 10 (71.4) | 0.486 | |
| Adjuvant target therapy | 7 (10.8) | 2 (14.3) | 0.657 | |
Values are presented as mean ± standard deviation or number (%).
BMI = body mass index; HER2 = human epidermal growth factor 2; LN = lymph node.
*Invasive carcinomas were only included.